NEW YORK (GenomeWeb) — Quidel said after the close of the market Tuesday that second quarter revenues rose 6 percent to $31.5 million compared to $29.7 million in the second quarter of 2013.

The increase in revenue was due to greater sales of infectious disease products in the second quarter of 2014, as well as growth in all other product segments, the company said.

In the quarter ended June 30, the company generated $3.8 million in total influenza product sales, the result of a 49 percent increase in international influenza orders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.